Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Proteinases in cardiovascular aneurysms and rupture: targets for therapy?
Peter Carmeliet
Peter Carmeliet
Published June 1, 2000
Citation Information: J Clin Invest. 2000;105(11):1519-1520. https://doi.org/10.1172/JCI10242.
View: Text | PDF
Commentary

Proteinases in cardiovascular aneurysms and rupture: targets for therapy?

  • Text
  • PDF
Abstract

Authors

Peter Carmeliet

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
(a) Proteinase inhibitors predominate in the quiescent vessel, while net...
(a) Proteinase inhibitors predominate in the quiescent vessel, while net proteolysis degrades the media and causes aneurysmal rupture during atherosclerosis. EC, endothelial cell; SMC, smooth muscle cell; Mφ, macrophage; EL, elastic lamina. (b) Inflammatory cells produce plasminogen (Plg) activators that activate plasmin, which degrades fibrin, laminin, and fibronectin. By activating zymogen pro-MMPs, plasmin orchestrates degradation of collagen and elastin, leading to complete destruction of all vessel wall matrix components.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts